Which has preferable valuation and earnings, SION or NVCT?

Sionna Therapeutics is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sionna Therapeutics N/A N/A -$75.27M -$1.93 N/A Nuvectis Pharma N/A N/A -$26.44M -$1.31 N/A

Is SION or NVCT more profitable?

Sionna Therapeutics' return on equity of -27.31% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Sionna Therapeutics N/A -27.31% -25.88% Nuvectis Pharma N/A -161.00% -98.88%

Does the media prefer SION or NVCT?

In the previous week, Nuvectis Pharma had 5 more articles in the media than Sionna Therapeutics. MarketBeat recorded 8 mentions for Nuvectis Pharma and 3 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 0.63 beat Nuvectis Pharma's score of 0.58 indicating that Sionna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvectis Pharma 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ABCL or NVCT?

In the previous week, Nuvectis Pharma had 5 more articles in the media than AbCellera Biologics. MarketBeat recorded 8 mentions for Nuvectis Pharma and 3 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.87 beat Nuvectis Pharma's score of 0.58 indicating that AbCellera Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvectis Pharma 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NVCT or BHC?

In the previous week, Nuvectis Pharma had 7 more articles in the media than Bausch Health Cos. MarketBeat recorded 8 mentions for Nuvectis Pharma and 1 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.71 beat Nuvectis Pharma's score of 0.58 indicating that Bausch Health Cos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch Health Cos 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, NVCT or HCM?

HUTCHMED has higher revenue and earnings than Nuvectis Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvectis Pharma N/A N/A -$26.44M -$1.31 N/A HUTCHMED $548.51M 3.43 $456.91M N/A N/A

Is NVCT or HCM more profitable?

HUTCHMED's return on equity of 0.00% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Nuvectis Pharma N/A -161.00% -98.88% HUTCHMED N/A N/A N/A

Does the media refer more to NVCT or HCM?

In the previous week, Nuvectis Pharma had 5 more articles in the media than HUTCHMED. MarketBeat recorded 8 mentions for Nuvectis Pharma and 3 mentions for HUTCHMED. Nuvectis Pharma's average media sentiment score of 0.58 beat HUTCHMED's score of 0.27 indicating that Nuvectis Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HUTCHMED 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Nuvectis Pharma (NVCT) Competitors

$18.39 -10.14 (-35.54%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$18.53 +0.14 (+0.74%)

As of 06/30/2026 07:44 PM Eastern

Compare

NVCT vs. SION, ABCL, BHC, ANAB, and HCM

Should you buy Nuvectis Pharma stock or one of its competitors? MarketBeat compares Nuvectis Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuvectis Pharma include Sionna Therapeutics (SION), AbCellera Biologics (ABCL), Bausch Health Cos (BHC), AnaptysBio (ANAB), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry.

How does Nuvectis Pharma compare to Sionna Therapeutics?

Sionna Therapeutics (NASDAQ:SION) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Sionna Therapeutics' return on equity of -27.31% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-27.31%	-25.88%
Nuvectis Pharma	N/A	-161.00%	-98.88%

In the previous week, Nuvectis Pharma had 5 more articles in the media than Sionna Therapeutics. MarketBeat recorded 8 mentions for Nuvectis Pharma and 3 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 0.63 beat Nuvectis Pharma's score of 0.58 indicating that Sionna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvectis Pharma	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sionna Therapeutics is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

Sionna Therapeutics currently has a consensus price target of $53.22, indicating a potential upside of 20.99%. Nuvectis Pharma has a consensus price target of $39.00, indicating a potential upside of 112.07%. Given Nuvectis Pharma's higher possible upside, analysts clearly believe Nuvectis Pharma is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Sionna Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.07, meaning that its share price is 107% less volatile than the broader market.

96.8% of Nuvectis Pharma shares are owned by institutional investors. 5.1% of Sionna Therapeutics shares are owned by insiders. Comparatively, 28.6% of Nuvectis Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Sionna Therapeutics and Nuvectis Pharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Nuvectis Pharma compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and Nuvectis Pharma (NASDAQ:NVCT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

AbCellera Biologics has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.07, meaning that its stock price is 107% less volatile than the broader market.

Nuvectis Pharma has a net margin of 0.00% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-181.75%	-14.86%	-10.62%
Nuvectis Pharma	N/A	-161.00%	-98.88%

In the previous week, Nuvectis Pharma had 5 more articles in the media than AbCellera Biologics. MarketBeat recorded 8 mentions for Nuvectis Pharma and 3 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.87 beat Nuvectis Pharma's score of 0.58 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvectis Pharma	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by company insiders. Comparatively, 28.6% of Nuvectis Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Nuvectis Pharma has lower revenue, but higher earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	31.88	-$146.41M	-$0.48	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

AbCellera Biologics presently has a consensus target price of $7.80, indicating a potential downside of 0.54%. Nuvectis Pharma has a consensus target price of $39.00, indicating a potential upside of 112.07%. Given Nuvectis Pharma's higher possible upside, analysts clearly believe Nuvectis Pharma is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

AbCellera Biologics beats Nuvectis Pharma on 9 of the 16 factors compared between the two stocks.

How does Nuvectis Pharma compare to Bausch Health Cos?

Nuvectis Pharma (NASDAQ:NVCT) and Bausch Health Cos (NYSE:BHC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

96.8% of Nuvectis Pharma shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 28.6% of Nuvectis Pharma shares are held by company insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Nuvectis Pharma presently has a consensus price target of $39.00, suggesting a potential upside of 112.07%. Bausch Health Cos has a consensus price target of $8.00, suggesting a potential upside of 62.44%. Given Nuvectis Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Nuvectis Pharma is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, Nuvectis Pharma had 7 more articles in the media than Bausch Health Cos. MarketBeat recorded 8 mentions for Nuvectis Pharma and 1 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.71 beat Nuvectis Pharma's score of 0.58 indicating that Bausch Health Cos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch Health Cos	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvectis Pharma has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. Nuvectis Pharma's return on equity of -161.00% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-161.00%	-98.88%
Bausch Health Cos	-11.47%	-2,922.77%	5.63%

Bausch Health Cos has higher revenue and earnings than Nuvectis Pharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Bausch Health Cos	$10.27B	0.18	$157M	-$3.24	N/A

Nuvectis Pharma has a beta of -0.07, indicating that its stock price is 107% less volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market.

Summary

Nuvectis Pharma beats Bausch Health Cos on 9 of the 15 factors compared between the two stocks.

How does Nuvectis Pharma compare to AnaptysBio?

AnaptysBio (NASDAQ:ANAB) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

In the previous week, Nuvectis Pharma had 7 more articles in the media than AnaptysBio. MarketBeat recorded 8 mentions for Nuvectis Pharma and 1 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 1.89 beat Nuvectis Pharma's score of 0.58 indicating that AnaptysBio is being referred to more favorably in the media.

Company	Overall Sentiment
AnaptysBio	Very Positive
Nuvectis Pharma	Positive

Nuvectis Pharma has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. Nuvectis Pharma's return on equity of -161.00% beat AnaptysBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	-1,101.24%	-7.75%
Nuvectis Pharma	N/A	-161.00%	-98.88%

AnaptysBio has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.07, meaning that its stock price is 107% less volatile than the broader market.

AnaptysBio has higher revenue and earnings than Nuvectis Pharma. AnaptysBio is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	8.37	-$13.23M	-$1.08	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

96.8% of Nuvectis Pharma shares are owned by institutional investors. 33.5% of AnaptysBio shares are owned by insiders. Comparatively, 28.6% of Nuvectis Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

AnaptysBio presently has a consensus target price of $81.82, suggesting a potential upside of 21.21%. Nuvectis Pharma has a consensus target price of $39.00, suggesting a potential upside of 112.07%. Given Nuvectis Pharma's higher probable upside, analysts clearly believe Nuvectis Pharma is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

AnaptysBio beats Nuvectis Pharma on 9 of the 15 factors compared between the two stocks.

How does Nuvectis Pharma compare to HUTCHMED?

Nuvectis Pharma (NASDAQ:NVCT) and HUTCHMED (NASDAQ:HCM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

HUTCHMED has higher revenue and earnings than Nuvectis Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
HUTCHMED	$548.51M	3.43	$456.91M	N/A	N/A

Nuvectis Pharma has a beta of -0.07, meaning that its share price is 107% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market.

Nuvectis Pharma currently has a consensus target price of $39.00, indicating a potential upside of 112.07%. HUTCHMED has a consensus target price of $16.80, indicating a potential upside of 55.70%. Given Nuvectis Pharma's higher possible upside, equities analysts clearly believe Nuvectis Pharma is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
HUTCHMED	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20

In the previous week, Nuvectis Pharma had 5 more articles in the media than HUTCHMED. MarketBeat recorded 8 mentions for Nuvectis Pharma and 3 mentions for HUTCHMED. Nuvectis Pharma's average media sentiment score of 0.58 beat HUTCHMED's score of 0.27 indicating that Nuvectis Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HUTCHMED	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 28.6% of Nuvectis Pharma shares are owned by company insiders. Comparatively, 3.6% of HUTCHMED shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

HUTCHMED's return on equity of 0.00% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-161.00%	-98.88%
HUTCHMED	N/A	N/A	N/A

Summary

HUTCHMED beats Nuvectis Pharma on 7 of the 12 factors compared between the two stocks.

Get Nuvectis Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVCT vs. The Competition

Export

Metric	Nuvectis Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$756.77M	$3.66B	$7.07B	$12.45B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-14.04	20.90	27.51	24.87
Price / Sales	N/A	341.80	540.69	102.84
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	25.54	8.75	11.01	6.54
Net Income	-$26.44M	$23.81M	$3.57B	$336.70M
7 Day Performance	-24.88%	3.60%	2.31%	2.88%
1 Month Performance	88.62%	3.72%	1.38%	0.64%
1 Year Performance	151.57%	68.80%	36.70%	31.34%

Nuvectis Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVCT Nuvectis Pharma	2.301 of 5 stars	$18.39 -35.5%	$39.00 +112.1%	+146.2%	$756.77M	N/A	N/A	8	News Coverage Gap Down High Trading Volume
SION Sionna Therapeutics	2.2986 of 5 stars	$39.87 +2.7%	$53.22 +33.5%	+153.5%	$1.75B	N/A	N/A	35	News Coverage
ABCL AbCellera Biologics	0.9617 of 5 stars	$5.63 -1.9%	$7.80 +38.5%	+128.6%	$1.75B	$75.13M	N/A	500	Options Volume Gap Down
BHC Bausch Health Cos	2.4799 of 5 stars	$4.79 +2.6%	$8.00 +67.0%	-26.3%	$1.75B	$10.27B	N/A	20,300
ANAB AnaptysBio	3.5274 of 5 stars	$59.43 -0.9%	$81.82 +37.7%	+204.1%	$1.75B	$234.60M	N/A	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NVCT) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvectis Pharma (NVCT) Competitors

NVCT vs. SION, ABCL, BHC, ANAB, and HCM

How does Nuvectis Pharma compare to Sionna Therapeutics?

Summary

How does Nuvectis Pharma compare to AbCellera Biologics?

Summary

How does Nuvectis Pharma compare to Bausch Health Cos?

Summary

How does Nuvectis Pharma compare to AnaptysBio?

Summary

How does Nuvectis Pharma compare to HUTCHMED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCT vs. The Competition

Nuvectis Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvectis Pharma (NVCT) Competitors

NVCT vs. SION, ABCL, BHC, ANAB, and HCM

How does Nuvectis Pharma compare to Sionna Therapeutics?

Is SION or NVCT more profitable?

Does the media prefer SION or NVCT?

Which has preferable valuation and earnings, SION or NVCT?

Do analysts prefer SION or NVCT?

Which has more risk & volatility, SION or NVCT?

Do institutionals and insiders have more ownership in SION or NVCT?

Summary

How does Nuvectis Pharma compare to AbCellera Biologics?

Which has more risk and volatility, ABCL or NVCT?

Is ABCL or NVCT more profitable?

Does the media favor ABCL or NVCT?

Do insiders & institutionals hold more shares of ABCL or NVCT?

Which has stronger valuation and earnings, ABCL or NVCT?

Do analysts prefer ABCL or NVCT?

Summary

How does Nuvectis Pharma compare to Bausch Health Cos?

Do institutionals & insiders have more ownership in NVCT or BHC?

Do analysts rate NVCT or BHC?

Does the media refer more to NVCT or BHC?

Is NVCT or BHC more profitable?

Which has better earnings and valuation, NVCT or BHC?

Which has more risk & volatility, NVCT or BHC?

Summary

How does Nuvectis Pharma compare to AnaptysBio?

Does the media prefer ANAB or NVCT?

Is ANAB or NVCT more profitable?

Which has more volatility and risk, ANAB or NVCT?

Which has preferable valuation & earnings, ANAB or NVCT?

Do insiders & institutionals have more ownership in ANAB or NVCT?

Do analysts prefer ANAB or NVCT?

Summary

How does Nuvectis Pharma compare to HUTCHMED?

Which has higher earnings & valuation, NVCT or HCM?

Which has more volatility & risk, NVCT or HCM?

Do analysts recommend NVCT or HCM?

Does the media refer more to NVCT or HCM?

Do institutionals and insiders believe in NVCT or HCM?

Is NVCT or HCM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCT vs. The Competition

Nuvectis Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools